Sino Biopharmaceutical Ltd
HKEX:1177
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.34
4.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sino Biopharmaceutical Ltd
Sino Biopharmaceutical Ltd
Net Issuance of Debt
Sino Biopharmaceutical Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Net Issuance of Debt
-¥1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Net Issuance of Debt
-HK$1.1B
|
CAGR 3-Years
-266%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Net Issuance of Debt
¥989.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Net Issuance of Debt
-¥1.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-33%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Net Issuance of Debt
-HK$8.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Net Issuance of Debt
$43.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sino Biopharmaceutical Ltd
Glance View
Sino Biopharmaceutical Ltd. emerged as a key player in the Chinese healthcare landscape, rooted in the rich cultural hubs of Beijing and Hong Kong. As the tapestry of modern medicine interweaves ever more tightly with advanced research, Sino Biopharmaceutical positions itself at this critical juncture. The company delves extensively into the discovery, development, manufacturing, and commercialization of a broad spectrum of pharmaceuticals. With a keen focus on therapeutic areas like oncology, hepatitis, and cardio-cerebral diseases, they forge pathways for innovative treatments that resonate widely in the fast-developing Chinese medical market. Driven by its Research and Development prowess, Sino Biopharmaceutical garners considerable strength from its portfolio of proprietary drugs, underscoring a growth strategy deeply rooted in innovation and quality. The financial blueprint of Sino Biopharmaceutical delicately balances its expansive production capacities with a robust distribution network, encapsulating an effective end-to-end operation from lab to patient. Revenue streams are predominantly anchored in its extensive sales of prescription drugs, particularly high-margin specialty pharmaceuticals that address critical and chronic health conditions. Leveraging strategic alliances and collaborations with both domestic and international partners, the company enhances its technological capabilities and global reach. Moreover, its enduring commitment to sustainable practices and compliance wields influence over its operational efficiencies, allowing Sino Biopharmaceutical to navigate and capitalize on regulatory environments while meeting the burgeoning healthcare needs across its business region.
See Also
What is Sino Biopharmaceutical Ltd's Net Issuance of Debt?
Net Issuance of Debt
-1.8B
CNY
Based on the financial report for Jun 30, 2024, Sino Biopharmaceutical Ltd's Net Issuance of Debt amounts to -1.8B CNY.
What is Sino Biopharmaceutical Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
-18%
Over the last year, the Net Issuance of Debt growth was -18%.
You don't have any saved screeners yet
